Sunday, July 12, 2009
EZH2 Protein Being Studied for Effect on Triple Negative
The protein EZH2 is expressed in a great majority (74 percent) of hormone-receptor-negative tumors, mostly triple negative tumors. It is linked to larger tumor size—more than 2 cm—and increased likelihood of spread to the lymph nodes, according to research presented at the 2009 annual meeting of the American Society of Clinical Oncology. “EZH2 could be an important therapeutic target in this patient population,” the researchers note. The study is ongoing with the goal to determine EZH2's role in survival.